Inventiva in Numbers
Innovative Clinical Programmes
People in our Scientific Team
A Library of
Welcome to Inventiva Pharma
We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.
We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.
By leveraging these assets and expertise, we are advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.About Inventiva
H1 2021 financial results
Share Information€12.3 +2.5%
Last update: May 17, 2021 at 17:38 CET
Previous close: €12.0
Day High: €12.3
Day Low: €11.96
Non-Alcoholic Steatohepatitis (NASH)
Inventiva is developing lanifibranor for the treatment of NASH to address all the key features of this disease: accumulation of liver fat (steatosis), inflammation (hepatitis), injury of liver cells (ballooning), as well as scarring of the liver (fibrosis) that can ultimately lead to cirrhosis. The progression of fibrosis to cirrhosis, and its complications, is especially relevant in determining the outcome of the disease with regard to morbidity and survival.
Lanifibranor has completed a phase IIb study. After only 6 months of treatment, lanifibranor showed statistically significant efficacy for both regulatory endpoints required by FDA and EMA: resolution of NASH* without worsening of fibrosis and reduction in fibrosis without worsening of NASH**. These efficacy results, together with a favorable safety profile, led to Breakthrough Therapy Designation by the FDA. For more details of the headline results see the results presentation.
Based on the positive results of the phase IIb study, Inventiva is currently preparing a pivotal phase III clinical trial, which is scheduled to start in the summer of 2021.
* Resolution of NASH and no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline (NAS-Fibrosis)
** Improvement of liver fibrosis ≥ 1 stage and no worsening of NASH at week 24
MPS is a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells.
Inventiva is developing odiparcil, an orally-available small molecule designed to modify how GAGs are synthesized.
In the recently completed iMProveS phase IIa study, odiparcil confirmed its favourable safety profile and demonstrated efficacy in adult MPS VI patients, especially in tissues types not reached by standard of care.
Phase IIb trial in NASH, enrollment completed
Phase IIa in adult MPSVI patients, completed
50 Rue de Dijon
21121 Daix, France
Email : email@example.com
Call : +33 (0)3 80 44 75 00